Andrä Claudia, Rauch Josefine, Li Minglun, Ganswindt Ute, Belka Claus, Saleh-Ebrahimi Ladan, Ballhausen Hendrik, Nachbichler Silke Birgit, Roeder Falk
Department of Radiation Oncology, University Hospital of LMU Munich, Marchioninistr, 15 81377, Munich, Germany.
Department of Molecular Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Radiat Oncol. 2015 Jul 10;10:140. doi: 10.1186/s13014-015-0449-x.
To report our results with postoperative or definitive radiation therapy in head and neck sarcomas.
We performed a retrospective analysis of 26 patients suffering from head and neck sarcomas, who received postoperative or definitive radiation therapy between 2003 and 2012. Median age was 64 years (19-88) and 69 % were male. Tumor locations were skull (including skin) in 31 %, paranasal sinus/orbita in 27 % and neck (including pharynx/larynx) in 42 %. Median tumor size was 4.6 cm (1-12 cm). 22 patients (85 %) presented in primary situation. Stage at presentation (UICC 7(th) for soft tissue sarcomas) was as follows: Ia:4 %, IIa:50 %, IIb:15 %, III:31 %. All except one patient suffered from high grade lesions (G2/3 FNCLCC), predominantly angiosarcoma (35 %), MFH (19 %) and synovial sarcoma (15 %). Surgery was performed in 21 pts (81 %), resulting in free margins in 10 (38 %), microscopically positive margins in 6 (23 %) and gross residual disease in 5 (19 %). Median dose to the primary tumor region was 66Gy (45-72Gy) in conventional fractionation, using 3D-CRT in 65 %, IMRT in 27 % and electrons in 8 %. 50 % of the patients also received sequential chemotherapy.
Median follow up was 39 months (8-136). We observed three local recurrences, transferring into estimated 3- and 5-year local control rates of 86 %. One additional patient failed distantly, resulting in 3- and 5-year freedom from treatment failure rates of 82 %. Four patients have deceased, transferring into 3- and 5-year overall survival rates of 88 % and 82 %, respectively. Only two of the four deaths were sarcoma related. Maximum acute toxicity (CTCAE 3.0) was grade 1 in 27 % of the patients, grade 2 in 50 % and grade 3 in 23 %. Severe acute toxicity was mainly represented by mucositis and dysphagia. Maximum late toxicity was grade 1 in 31 %, grade 2 in 15 % and grade 3 in 19 % of the patients. Severe late toxicity included skin ulceration (n = 1), dysphagia with persistent tube dependency (n = 1), persistent sinusitis (n = 1) and hearing loss (n = 2).
Excellent local control and overall survival rates can be achieved with postoperative or definitive radiation therapy with acceptable acute and late toxicities in patients suffering from sarcomas of the head and neck region.
报告我们对头颈部肉瘤进行术后或根治性放射治疗的结果。
我们对26例头颈部肉瘤患者进行了回顾性分析,这些患者在2003年至2012年间接受了术后或根治性放射治疗。中位年龄为64岁(19 - 88岁),69%为男性。肿瘤部位分布如下:颅骨(包括皮肤)占31%,鼻窦/眼眶占27%,颈部(包括咽/喉)占42%。中位肿瘤大小为4.6厘米(1 - 12厘米)。22例(85%)为初发情况。就诊时的分期(软组织肉瘤采用国际抗癌联盟第7版分期)如下:Ia期:4%,IIa期:50%,IIb期:15%,III期:31%。除1例患者外,所有患者均为高级别病变(G2/3,法国国立癌症中心联合会分级),主要为血管肉瘤(35%)、恶性纤维组织细胞瘤(19%)和滑膜肉瘤(15%)。21例患者(81%)接受了手术,其中10例(38%)切缘阴性,6例(23%)镜下切缘阳性,5例(19%)有肉眼残留病灶。原发肿瘤区域的中位剂量在常规分割照射下为66Gy(45 - 72Gy),其中65%采用三维适形放疗(3D - CRT),27%采用调强放疗(IMRT),8%采用电子线放疗。50%的患者还接受了序贯化疗。
中位随访时间为39个月(8 - 136个月)。我们观察到3例局部复发,由此得出估计的3年和5年局部控制率为86%。另有1例患者远处转移失败,3年和5年无治疗失败率为82%。4例患者死亡,3年和5年总生存率分别为为88%和82%。4例死亡患者中只有2例与肉瘤相关。最大急性毒性(美国国立癌症研究所常见不良反应事件评价标准3.0版)在27%的患者中为1级,50%为2级,23%为3级。严重急性毒性主要表现为黏膜炎和吞咽困难。最大晚期毒性在31%的患者中为1级,15%为2级,19%为3级。严重晚期毒性包括皮肤溃疡(1例)、吞咽困难且持续依赖胃管(1例)、持续性鼻窦炎(例)和听力丧失(2例)。
对头颈部肉瘤患者进行术后或根治性放射治疗可取得优异的局部控制率和总生存率,且急性和晚期毒性均可接受。